53 results on '"Bacigalupo, Andrea"'
Search Results
2. Upfront Alternative Donor Transplant versus Immunosuppressive Therapy in Patients with Severe Aplastic Anemia Who Lack a Fully HLA-Matched Related Donor: Systematic Review and Meta-Analysis of Retrospective Studies, on Behalf of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation.
- Author
-
Alotaibi H, Aljurf M, de Latour R, Alfayez M, Bacigalupo A, Fakih RE, Schrezenmeier H, Ahmed SO, Gluckman E, Iqbal S, Höchsmann B, Halkes C, de la Fuente J, Alshehry N, Cesaro S, Passweg J, Dufour C, Risitano AM, DiPersio J, and Motabi I
- Subjects
- Bone Marrow, Child, Humans, Immunosuppression Therapy, Retrospective Studies, Anemia, Aplastic therapy, Graft vs Host Disease epidemiology
- Abstract
Idiopathic aplastic anemia is a rare and life-threatening disorder, and hematopoietic stem cell transplantation (HSCT) from a matched sibling donor (MSD) is the standard treatment strategy for young patients. Alternative donor transplantation (ADT) from a matched unrelated donor or an HLA haploidentical donor is not commonly used in the frontline setting. This systematic review/meta-analysis was conducted to compare ADT as an upfront, rather than delayed, treatment strategy in the absence of an MSD to immunosuppressive therapy (IST) in severe aplastic anemia (SAA). We searched PubMed/MEDLINE and Embase (1998 to 2019) for studies that compared the outcomes of ADT with IST as upfront therapy in patients with SAA. We included studies with 5 patients or more in each arm. Studies that included patients with inherited forms of bone marrow failure syndromes were excluded. The primary outcome was the 5-year overall survival (OS) rate. Five studies met the inclusion criteria and were included in this meta-analysis. The pooled 5-year odds ratio (OR) for OS was statistically significant at 0.44 (95% confidence interval [CI], 0.23 to 0.85) in favor of upfront ADT. In addition, survival was compared between upfront ADT versus salvage ADT in 6 studies. The pooled 5-year OR for OS was statistically significant at 0.31 (95% CI, 0.15 to 0.64) in favor of upfront ADT. Although this analysis has some limitations, including the retrospective nature of the included studies, the lack of ethnic diversity, the predominantly pediatric population, and the relatively suboptimal IST regimen used in some of the studies, it indicates that upfront ADT is a potential alternative treatment option in young and pediatric SAA patients who lack an HLA identical sibling donor, particularly when optimal IST is not available. © 2021 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc., (Copyright © 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
3. Special issues related to the diagnosis and management of acquired aplastic anemia in countries with restricted resources, a report on behalf of the Eastern Mediterranean blood and marrow transplantation (EMBMT) group and severe aplastic anemia working party of the European Society for blood and marrow transplantation (SAAWP of EBMT).
- Author
-
Iftikhar R, Ahmad P, de Latour R, Dufour C, Risitano A, Chaudhri N, Bazarbachi A, De La Fuente J, Höchsmann B, Osman Ahmed S, Gergis U, Elhaddad A, Halkes C, Albeirouti B, Alotaibi S, Kulasekararaj A, Alzahrani H, Ben Othman T, Cesaro S, Alahmari A, Rihani R, Alshemmari S, Hamidieh AA, Bekadja MA, Passweg J, Al-Khabori M, Rasheed W, Bacigalupo A, Chaudhry QU, Ljungman P, Marsh J, El Fakih R, and Aljurf M
- Subjects
- Bone Marrow, Bone Marrow Failure Disorders, Bone Marrow Transplantation, Humans, Transplantation Conditioning, Anemia, Aplastic diagnosis, Anemia, Aplastic therapy, Hematopoietic Stem Cell Transplantation
- Abstract
Aplastic anemia is a relatively rare but potentially fatal disorder, with a reported higher incidence in developing countries in comparison to the West. There are significant variations in epidemiological as well as etiological factors of bone marrow failure syndromes in the developing countries in comparison to the developed world. Furthermore, the management of bone marrow failure syndromes in resource constraint settings has significant challenges including delayed diagnosis and referral, limited accessibility to healthcare facilities, treatment modalities as well as limitations related to patients who require allogeneic stem cell transplantation. Here we will provide a review of the available evidence related to specific issues of aplastic anemia in the developing countries and we summarize suggested recommendations from the Eastern Mediterranean blood and bone marrow transplantation (EMBMT) group and the severe aplastic anemia working party of the European Society of blood and marrow transplantation (SAAWP of EBMT) related to the diagnosis and therapeutic options in countries with restricted resources., (© 2021. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2021
- Full Text
- View/download PDF
4. Bone marrow transplantation for acquired aplastic anemia: What's new.
- Author
-
Bacigalupo A and Benintende G
- Subjects
- Adult, Bone Marrow Transplantation, Cyclophosphamide, Humans, Transplantation Conditioning, Anemia, Aplastic therapy, Graft vs Host Disease prevention & control
- Abstract
Bone marrow transplantation is a major therapeutic option for patients with acquired severe aplastic anaemia: improved survival has been achieved in younger patients, thanks to better donor selection, conditioning regimens and graft versus host disease prophylaxis, together with improved supportive care, including diagnosis and treatment of opportunistic infections. This has not been the case for older patients over the age of 40 years. We will discuss transplantation platforms as used for different donor types and we will analyse major breakthroughs of the last years: the combination of Fludarabine and cyclophosphamide as a conditioning regimen, the use of alternative donors including HLA haploidentical related donors and new strategies to prevent acute and chronic graft versus host disease, including post transplantation Cyclophosphamide. These changes extend the option of a bone marrow transplantation for patients who lack an HLA matched donor and appear to improve engraftment and reduce graft versus host disease: whether this will be true for all age groups is currently being investigated., (Copyright © 2021. Published by Elsevier Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
5. Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT).
- Author
-
ElGohary G, El Fakih R, de Latour R, Risitano A, Marsh J, Schrezenmeier H, Gluckman E, Höchsmann B, Pierri F, Halkes C, Alzahrani H, De la Fuente J, Cesaro S, Alahmari A, Ahmed SO, Passweg J, Dufour C, Bacigalupo A, and Aljurf M
- Subjects
- Bone Marrow, Female, Humans, Male, Transplantation Conditioning, Anemia, Aplastic therapy, Graft vs Host Disease prevention & control, Hematopoietic Stem Cell Transplantation
- Abstract
Aplastic anemia (AA) is a serious hematological disorder, which is solely cured by hematopoietic stem cell transplantation (HSCT). Haploidentical HSCT is an emerging modality with encouraging outcomes in several blood conditions. The present study aims to comprehensively assess the feasibility and safety of haploidentical HSCT in patients with severe and very severe AA. It is a systematic review and meta-analysis of studies related to haploidentical stem cell transplantation in idiopathic AA investigating rates of successful engraftment, acute graft-versus-host disease (aGvHD), chronic GvHD (cGvHD), transplant-related mortality (TRM), and posttransplantation viral infections (including cytomegalovirus [CMV]) in patients with AA. The effects of reduced-intensity conditioning (RIC) and nonmyeloablative conditioning (NMA), as well as various GvHD prophylaxis regimens on these outcomes were evaluated. In total 15 studies were identified, (577 patients, 58.9% males), successful engraftment was observed in 97.3% of patients (95% CI, 95.9-98.7) while grades II-IV aGvHD and cGvHD were reported in 26.6% and 25.0%, respectively. The pooled incidence of TRM was 6.7% per year (95% CI, 4.0-9.4). RIC regimens were associated with higher proportions of successful engraftment (97.7% vs 91.7%, P = 0.03) and aGvHD (29.5% vs 18.7%, P = 0.008) when compared with NMA regimens with no differences in cGvHD or mortality incidence. When compared with methotrexate-containing regimens and other regimens, posttransplant cyclophosphamide-containing regimens reduced the rates of aGvHD (28.6%, 27.8%, and 12.8%, respectively, P = 0.02), CMV viremia (55.7%, 38.6%, and 10.4%, respectively, P < 0.001), and CMV disease in initially viremic patients (2.1%, 33.0%, and 0%, respectively, P < 0.001). We have concluded that Haploidentical HSCT was associated with promising outcomes in terms of successful engraftment and reduced complications. Future prospective trials are needed to identify the preferred conditioning regimen, GvHD prophylaxis, and graft source in the setting of haploidentical transplant for AA.
- Published
- 2020
- Full Text
- View/download PDF
6. A 30-month-old boy with aplastic anemia caused by electrocution.
- Author
-
Servatyari K, Moradveisi B, Yazdanpanah H, and Bacigalupo A
- Subjects
- Allografts, Anemia, Aplastic therapy, Child, Preschool, Electric Injuries blood, Hematopoietic Stem Cell Transplantation, Humans, Male, Anemia, Aplastic etiology, Electric Injuries complications
- Published
- 2020
- Full Text
- View/download PDF
7. Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation.
- Author
-
Tichelli A, de Latour RP, Passweg J, Knol-Bout C, Socié G, Marsh J, Schrezenmeier H, Höchsmann B, Bacigalupo A, Samarasinghe S, Rovó A, Kulasekararaj A, Röth A, Eikema DJ, Bosman P, Bader P, Risitano A, and Dufour C
- Subjects
- Bone Marrow, Cyclosporine therapeutic use, Follow-Up Studies, Granulocyte Colony-Stimulating Factor, Granulocytes, Humans, Immunosuppressive Agents therapeutic use, Prospective Studies, Anemia, Aplastic diagnosis, Anemia, Aplastic drug therapy, Anemia, Aplastic epidemiology, Antilymphocyte Serum therapeutic use
- Abstract
This follow-up study of a randomized, prospective trial included 192 patients with newly diagnosed severe aplastic anemia receiving antithymoglobulin and cyclosporine, with or without granulocyte colony-stimulating factor (G-CSF). We aimed to evaluate the long-term effect of G-CSF on overall survival, event-free survival, probability of secondary myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), clinical paroxysmal nocturnal hemoglobinuria, relapse, avascular osteonecrosis and chronic kidney disease. The median follow-up was 11.7 years (95% CI, 10.9-12.5). The overall survival rate at 15 years was 57±12% in the group given G-CSF and 63±12% in the group not given G-CSF ( P =0.92); the corresponding event-free survival rates were 24±10% and 23±10%, respectively ( P =0.36). In total, 9 patients developed MDS or AML, 10 only a clonal cytogenetic abnormality, 7 a solid cancer, 18 clinical paroxysmal nocturnal hemoglobinuria, 8 osteonecrosis, and 12 chronic kidney disease, without any difference between patients treated with or without G-CSF. The cumulative incidence of MDS, AML or isolated cytogenetic abnormality at 15 years was 8.5±3% for the G-CSF group and 8.2±3% for the non-G-CSF group ( P =0.90). The cumulative incidence of any late event including myelodysplastic syndrome or acute myeloid leukemia, isolated cytogenetic abnormalities, solid cancer, clinical paroxysmal nocturnal hemoglobinuria, aseptic osteonecrosis, chronic kidney disease and relapse was 50±12% for the G-CSF group and 49±12% for the non-G-CSF group ( P =0.65). Our results demonstrate that it is unlikely that G-CSF has an impact on the outcome of severe aplastic anemia; nevertheless, very late events are common and eventually affect the prognosis of these patients, irrespectively of their age at the time of immunosuppressive therapy (NCT01163942)., (Copyright© 2020 Ferrata Storti Foundation.)
- Published
- 2020
- Full Text
- View/download PDF
8. Haploidentical donor transplants for severe aplastic anemia.
- Author
-
Bacigalupo A and Giammarco S
- Subjects
- Adolescent, Child, Child, Preschool, Female, Humans, Male, Tissue Donors, Young Adult, Anemia, Aplastic therapy, Hematopoietic Stem Cell Transplantation methods, Transplantation Conditioning methods
- Abstract
Haploidentical stem cell transplantation (HAPLO) is being increasingly used, and significant progress has been made both with ex vivo T-cell depleted grafts as well as with unmanipulated marrow or peripheral blood grafts. We here review the current status of HAPLO grafts in patients with acquired severe aplastic anemia. Several transplant platforms have been tested, to overcome graft severe rejection and graft vs host disease (GvHD): these include differences in the conditioning regimen, in graft source and graft manipulation, and in GvHD prophylaxis. The latter include ex vivo T-cell depletion and/or antithymocyte globulin and/or high dose post-transplant cyclophosphamide. Some programs also include the use of marrow or cord blood mesenchymal stem cells, infused at the time of transplantation. Extremely encouraging results are being reported especially in the pediatric population, but also in young adults: we will review reports on 375 patients, with an average rejection rate of 6%, grade II-IV GvHD of 23% and 1-year survival of 80%. Finally we will discuss the place of HAPLO transplants in the context of alternative donor grafts for acquired aplastic anemia., (Copyright © 2019. Published by Elsevier Inc.)
- Published
- 2019
- Full Text
- View/download PDF
9. Antithymocyte globulin and cyclosporin: standard of care also for older patients with aplastic anemia.
- Author
-
Bacigalupo A
- Subjects
- Aged, Cyclosporine, Humans, Immunosuppressive Agents, Standard of Care, Surveys and Questionnaires, Anemia, Aplastic, Antilymphocyte Serum
- Published
- 2019
- Full Text
- View/download PDF
10. Alternative donor transplants for severe aplastic anemia.
- Author
-
Bacigalupo A
- Subjects
- Allografts, Anemia, Aplastic blood, Anemia, Aplastic pathology, Antilymphocyte Serum therapeutic use, Cyclosporine therapeutic use, Graft vs Host Disease blood, Graft vs Host Disease pathology, Graft vs Host Disease prevention & control, Humans, Severity of Illness Index, Anemia, Aplastic therapy, Hematopoietic Stem Cell Transplantation, Unrelated Donors
- Abstract
Allogeneic hematopoietic stem-cell transplantation remains the only curative treatment for patients with acquired severe aplastic anemia (SAA). When a matched sibling is not available, one can search for a matched unrelated donor or a cord blood unit (CB) in the international registries or, more recently, for an HLA haploidentical (HAPLO) family member. International guidelines call for a course of antithymocyte globulin (ATG) and cyclosporine before a patient with SAA receives a transplant from a donor other than an HLA identical sibling, but whether this is necessary for patients age <20 years is less clear. Here I will examine the rapid increase in HAPLO transplantations for SAA, showing encouraging early results both in children and young adults. Graft-versus-host disease prophylaxis remains of primary importance in patients with SAA, and in vivo T-cell depletion with either ATG or alemtuzumab offers a significant survival advantage. Finally, I will discuss the strong age effect, which is particularly evident at >40 and 50 years of age for reasons not entirely clear and which should be taken into account when designing a treatment strategy for a given patient., Competing Interests: Conflict-of-interest disclosure: A.B. declares no competing financial interests., (© 2018 by The American Society of Hematology. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
11. First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012.
- Author
-
Bacigalupo A, Oneto R, Schrezenmeier H, Hochsmann B, Dufour C, Kojima S, Zhu X, Chen X, Issaragrisil S, Chuncharunee S, Jeong DC, Giammarco S, Van Lint MT, Zheng Y, and Vallejo C
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Anemia, Aplastic mortality, Asia, Child, Child, Preschool, Europe, Humans, Infant, Middle Aged, Prognosis, Risk Factors, Survival Analysis, Treatment Outcome, Young Adult, Anemia, Aplastic drug therapy, Antilymphocyte Serum therapeutic use, Cyclosporine therapeutic use, Drug Therapy, Combination methods
- Abstract
The aim of this study was to assess the outcome of patients with aplastic anemia (AA), receiving rabbit anti-thymocyte globulin (Thymoglobulin, SANOFI) and cyclosporin, as first line treatment. Eligible were 955 patients with AA, treated first line with Thymoglobulin, between 2001 and 2008 (n = 492), or between 2009 and 2012 (n = 463). The median age of the patients was 21 years (range 1-84). Mortality within 90 days was 5.7% and 2.4%, respectively in the two time periods (P = .007).The actuarial 10-year survival for the entire population was 70%; transplant free survival was 64%. Predictors of survival in multivariate analysis, were severity of the disease, patients age and the interval between diagnosis and treatment. Survival was 87% vs 61% for responders at 6 months versus nonresponders (P < .0001). The 10-year survival of nonresponders at 6 months, undergoing a subsequent transplant (n = 110), was 64%, vs 60% for patient not transplantated (n = 266) (P = .1). The cumulative incidence of response was 37%, 52%, 65% respectively, at 90, 180, and 365 days. In multivariate analysis, negative predictors of response at 6 months, were older age, longer interval diagnosis treatment, and greater severity of the disease. In conclusion, early mortality is low after first line treatment of AA with Thymoglobulin, and has been further reduced after year 2008. Patients age, together with interval diagnosis-treament and severity of the disease, remain strong predictors of response and survival., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
12. Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?
- Author
-
Giammarco S, Peffault de Latour R, Sica S, Dufour C, Socie G, Passweg J, Kröger N, Petersen E, Van Lint MT, Oneto R, Signori A, and Bacigalupo A
- Subjects
- Aged, Allografts, Disease-Free Survival, Female, Humans, Male, Middle Aged, Retrospective Studies, Survival Rate, Anemia, Aplastic mortality, Anemia, Aplastic therapy, Hematopoietic Stem Cell Transplantation
- Published
- 2018
- Full Text
- View/download PDF
13. Antithymocyte globulin and transplants for aplastic anemia.
- Author
-
Bacigalupo A
- Subjects
- Humans, Immunosuppressive Agents, Anemia, Aplastic, Antilymphocyte Serum
- Published
- 2017
- Full Text
- View/download PDF
14. How I treat acquired aplastic anemia.
- Author
-
Bacigalupo A
- Subjects
- Anemia, Aplastic drug therapy, Bone Marrow Transplantation adverse effects, Bone Marrow Transplantation methods, Humans, Immunosuppression Therapy adverse effects, Immunosuppression Therapy methods, Treatment Outcome, Anemia, Aplastic therapy
- Abstract
Acquired severe aplastic anemia (SAA) is a rare hematologic disease associated with significant morbidity and mortality. Immune destruction of hemopoietic stem cells plays an important role in pathogenesis, as shown by successful treatment with immunosuppressive agents, leading to transfusion independence or complete recovery of peripheral blood counts in a proportion of patients. Growth factors can be combined with immunosuppressive therapy (IST) and may improve response rates, as recently shown with thrombopoietin analogs. Anabolic steroids may still play a role in combination with IST. The problem with IST is failure to respond and the development of late clonal disorders. Bone marrow transplantation (BMT) is the other therapeutic option: a matched sibling donor remains the best choice. For patients lacking a matched family donor, unrelated donors can be readily found, although mostly for patients of Caucasian origin. Other BMT options include unrelated cord blood or mismatched family donors. Acute and chronic graft-versus-host disease remain important complications of BMT. Patient age is a strong predictor of outcome for both IST and BMT, and must be considered when designing therapeutic strategies. Early diagnosis and treatment, as well as long-term monitoring, remain crucial steps for successful treatment of SAA., (© 2017 by The American Society of Hematology.)
- Published
- 2017
- Full Text
- View/download PDF
15. Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia.
- Author
-
Bacigalupo A, Giammarco S, and Sica S
- Subjects
- Anemia, Aplastic mortality, Bone Marrow Transplantation adverse effects, Bone Marrow Transplantation standards, Humans, Immunosuppression Therapy adverse effects, Immunosuppression Therapy standards, Immunosuppressive Agents therapeutic use, Treatment Outcome, Anemia, Aplastic therapy, Bone Marrow Transplantation methods, Immunosuppression Therapy methods
- Abstract
Standard front-line treatment for acquired aplastic anemia (AA) for patients is either immunosuppressive therapy (IST) or bone marrow transplantation (BMT), usually from an HLA identical sibling. Whereas long-term survival is comparable with either treatment, important differences remain: IST patients may have incomplete or no recovery, are exposed to late clonal disorders and relapse of the original disease. Transplantation is a curative treatment, but patients are exposed to transplant-related complications both acute and chronic, such as chronic graft versus host disease (cGvHD). In the year 2000, a study by the European Group for Blood and Marrow Transplantation (EBMT), looked at failure free survival (FFS), in patients receiving first-line BMT from an HLA identical sibling, or the first-line IST. Young patients with low neutrophil counts benefited of the first-line BMT; the opposite was true for older patients with higher neutrophil counts; and a third intermediate group of patients had comparable survival irrespective of the first-line therapy. We have now studied a more recent cohort of patients to assess whether things have changed over the years. We have found similar results, although overall survival has improved, as a consequence of changes in the IST and BMT protocols.
- Published
- 2016
- Full Text
- View/download PDF
16. Alternative donor transplants for severe aplastic anemia: current experience.
- Author
-
Bacigalupo A and Sica S
- Subjects
- Bone Marrow, Bone Marrow Transplantation, Hematopoietic Stem Cell Transplantation methods, Histocompatibility Antigens immunology, Humans, Siblings, Unrelated Donors, Anemia, Aplastic therapy
- Abstract
Patients with acquired severe aplastic anemia (SAA), who lack a human leukocyte antigen (HLA) identical sibling donor (SIB), have two therapeutic options: immunosuppressive therapy with anti-thymocyte globulin (ATG) and cyclosporine (CsA), or a transplant from an alternative donor. In these patients, the current guidelines of the European Group for Blood and Marrow Transplantation (EBMT) call for a course of ATG + CsA first and transplantation in case of no response. The alternative donor source can be an unrelated donor (UD), a cord blood (CB) unit, or a family mismatched member, in most instances genetically HLA haplo-mismatched (HAPLO). In the present review, we will discuss recent results of transplants from matched UD and SIB donors, with significantly improved outcome, especially with UD in the past decade. We will also be looking at CB transplants, and the problems of limited stem cell dose. Finally HAPLO grafts have been explored in patients lacking or having rejected an unrelated or CB graft: early results seem encouraging, though the procedure should still be considered experimental., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
17. Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT.
- Author
-
Dufour C, Veys P, Carraro E, Bhatnagar N, Pillon M, Wynn R, Gibson B, Vora AJ, Steward CG, Ewins AM, Hough RE, de la Fuente J, Velangi M, Amrolia PJ, Skinner R, Bacigalupo A, Risitano AM, Socie G, Peffault de Latour R, Passweg J, Rovo A, Tichelli A, Schrezenmeier H, Hochsmann B, Bader P, van Biezen A, Aljurf MD, Kulasekararaj A, Marsh JC, and Samarasinghe S
- Subjects
- Adenoviridae Infections drug therapy, Adenoviridae Infections epidemiology, Adolescent, Adult, Anemia, Aplastic mortality, Antilymphocyte Serum, Blood Transfusion statistics & numerical data, Bone Marrow Transplantation adverse effects, Case-Control Studies, Child, Child, Preschool, Cyclosporine therapeutic use, Disease-Free Survival, Female, Follow-Up Studies, Graft vs Host Disease drug therapy, Graft vs Host Disease epidemiology, Graft vs Host Disease prevention & control, Herpesviridae Infections drug therapy, Herpesviridae Infections epidemiology, Histocompatibility, Humans, Immunosuppressive Agents therapeutic use, Infant, Kaplan-Meier Estimate, Length of Stay statistics & numerical data, Living Donors, Male, Peripheral Blood Stem Cell Transplantation adverse effects, Postoperative Complications drug therapy, Postoperative Complications epidemiology, Primary Graft Dysfunction epidemiology, Quality of Life, Retrospective Studies, Siblings, Survival Rate, T-Lymphocytes, Treatment Outcome, Virus Activation, Young Adult, Anemia, Aplastic therapy, Bone Marrow Transplantation statistics & numerical data, Peripheral Blood Stem Cell Transplantation statistics & numerical data
- Abstract
We explored the feasibility of unrelated donor haematopoietic stem cell transplant (HSCT) upfront without prior immunosuppressive therapy (IST) in paediatric idiopathic severe aplastic anaemia (SAA). This cohort was then compared to matched historical controls who had undergone first-line therapy with a matched sibling/family donor (MSD) HSCT (n = 87) or IST with horse antithymocyte globulin and ciclosporin (n = 58) or second-line therapy with unrelated donor HSCT post-failed IST (n = 24). The 2-year overall survival in the upfront cohort was 96 ± 4% compared to 91 ± 3% in the MSD controls (P = 0·30) and 94 ± 3% in the IST controls (P = 0·68) and 74 ± 9% in the unrelated donor HSCT post-IST failure controls (P = 0·02).The 2-year event-free survival in the upfront cohort was 92 ± 5% compared to 87 ± 4% in MSD controls (P = 0·37), 40 ± 7% in IST controls (P = 0·0001) and 74 ± 9% in the unrelated donor HSCT post-IST failure controls (n = 24) (P = 0·02). Outcomes for upfront-unrelated donor HSCT in paediatric idiopathic SAA were similar to MSD HSCT and superior to IST and unrelated donor HSCT post-IST failure. Front-line therapy with matched unrelated donor HSCT is a novel treatment approach and could be considered as first-line therapy in selected paediatric patients who lack a MSD., (© 2015 John Wiley & Sons Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
18. Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis.
- Author
-
Bacigalupo A, Socié G, Hamladji RM, Aljurf M, Maschan A, Kyrcz-Krzemien S, Cybicka A, Sengelov H, Unal A, Beelen D, Locasciulli A, Dufour C, Passweg JR, Oneto R, Signori A, and Marsh JC
- Subjects
- Anemia, Aplastic epidemiology, Europe epidemiology, Female, Graft Survival, Graft vs Host Disease epidemiology, Graft vs Host Disease etiology, HLA Antigens genetics, HLA Antigens immunology, Humans, Incidence, Male, Risk Factors, Survival Analysis, Transplantation Conditioning methods, Transplantation, Homologous, Treatment Outcome, Anemia, Aplastic mortality, Anemia, Aplastic therapy, Hematopoietic Stem Cell Transplantation adverse effects, Siblings, Unrelated Donors
- Abstract
We have analyzed 1448 patients with acquired aplastic anemia grafted between 2005 and 2009, and compared outcome of identical sibling (n=940) versus unrelated donor (n=508) transplants. When compared to the latter, sibling transplants were less likely to be performed beyond 180 days from diagnosis (39% vs. 85%), to have a cytomegalovirus negative donor/recipient status (15% vs. 23%), to receive antithymocyte globulin in the conditioning (52% vs. 61%), and more frequently received marrow as a stem cell source (60% vs. 52%). Unrelated donor grafts had significantly more acute grade II-IV (25% vs. 13%) and significantly more chronic graft-versus-host disease (26% vs. 14%). In multivariate analysis, the risk of death of unrelated donor grafts was higher, but not significantly higher, compared to a sibling donor (P=0.16). The strongest negative predictor of survival was the use of peripheral blood as a stem cell source (P<0.00001), followed by an interval of diagnosis to transplant of 180 days or more (P=0.0005), patient age 20 years or over (P=0.0005), no antithymocyte globulin in the conditioning (P=0.003), and donor/recipient cytomegalovirus sero-status, other than negative/negative (P=0.04). In conclusion, in multivariate analysis, the outcome of unrelated donor transplants for acquired aplastic anemia, is currently not statistically inferior when compared to sibling transplants, although patients are at greater risk of acute and chronic graft-versus-host disease. The use of peripheral blood grafts remains the strongest negative predictor of survival., (Copyright© Ferrata Storti Foundation.)
- Published
- 2015
- Full Text
- View/download PDF
19. Outcome of aplastic anaemia in children. A study by the severe aplastic anaemia and paediatric disease working parties of the European group blood and bone marrow transplant.
- Author
-
Dufour C, Pillon M, Sociè G, Rovò A, Carraro E, Bacigalupo A, Oneto R, Passweg J, Risitano A, Tichelli A, Peffault de Latour R, Schrezenmeier H, Hocshmann B, Peters C, Kulasekararaj A, Van Biezen A, Samarasinghe S, Hussein AA, Ayas M, Aljurf M, and Marsh J
- Subjects
- Allografts, Child, Child, Preschool, Disease-Free Survival, Europe epidemiology, Female, Graft Rejection therapy, Graft vs Host Disease therapy, Humans, Infant, Infant, Newborn, Male, Survival Rate, Anemia, Aplastic mortality, Anemia, Aplastic therapy, Databases, Factual, Graft Rejection mortality, Graft vs Host Disease mortality, Hematopoietic Stem Cell Transplantation, Immunosuppression Therapy
- Abstract
This study analysed the outcome of 563 Aplastic Anaemia (AA) children aged 0-12 years reported to the Severe Aplastic Anaemia Working Party database of the European Society for Blood and Marrow Transplantation, according to treatment received. Overall survival (OS) after upfront human leucocyte antigen-matched family donor (MFD) haematopoietic stem cell transplantation (HSCT) or immunosuppressive treatment (IST) was 91% vs. 87% (P 0·18). Event-free survival (EFS) after upfront MFD HSCT or IST was 87% vs. 33% (P 0·001). Ninety-one of 167 patients (55%) failed front-line IST and underwent rescue HSCT. The OS of this rescue group was 83% compared with 91% for upfront MFD HSCT patients and 97% for those who did not fail IST up-front (P 0·017). Rejection was 2% for MFD HSCT and HSCT post-IST failure (P 0·73). Acute graft-versus-host disease (GVHD) grade II-IV was 8% in MFD graft vs. 25% for HSCT post-IST failure (P < 0·0001). Chronic GVHD was 6% in MFD HSCT vs. 20% in HSCT post-IST failure (P < 0·0001). MFD HSCT is an excellent therapy for children with AA. IST has a high failure rate, but remains a reasonable first-line choice if MFD HSCT is not available because high OS enables access to HSCT, which is a very good rescue option., (© 2015 John Wiley & Sons Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
20. Bone marrow transplantation for acquired severe aplastic anemia.
- Author
-
Bacigalupo A
- Subjects
- Anemia, Aplastic pathology, Bone Marrow Transplantation adverse effects, Graft vs Host Disease etiology, Graft vs Host Disease prevention & control, Histocompatibility Testing, Humans, Severity of Illness Index, Siblings, Survival Analysis, Tissue Donors, Transplantation Conditioning methods, Anemia, Aplastic therapy, Bone Marrow Transplantation methods
- Abstract
This article addresses current transplant options for patients with acquired severe aplastic anemia (SAA). This discussion includes ongoing progress in the use of SAA in the setting of unrelated donor transplants, which now provide outcomes similar, though still not identical, to HLA-identical sibling transplants. Recent data on stem cell source, conditioning regimens, and graft-versus-host disease prophylaxis are outlined. Other donor types such as cord blood and haploidentical mismatched family donors are also discussed., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
21. Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation.
- Author
-
Dufour C, Pillon M, Passweg J, Socié G, Bacigalupo A, Franceschetto G, Carraro E, Oneto R, Risitano AM, Peffault de Latour R, Tichelli A, Rovo A, Peters C, Hoechsmann B, Samarasinghe S, Kulasekararaj AG, Schrezenmeier H, Aljurf M, and Marsh J
- Subjects
- Adolescent, Anemia, Aplastic mortality, Anemia, Aplastic therapy, Bone Marrow Transplantation, Child, Female, Graft Rejection, Graft vs Host Disease etiology, Health Care Surveys, Hematologic Neoplasms etiology, Hematopoietic Stem Cell Transplantation adverse effects, Humans, Incidence, Male, Patient Outcome Assessment, Prognosis, Transplantation Conditioning, Treatment Outcome, Young Adult, Anemia, Aplastic epidemiology
- Abstract
We analyzed the outcome of 537 adolescents (age 12-18 years) with idiopathic aplastic anemia included in the database of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation comparing: i) matched family donor hematopoietic stem cell transplantation performed as first-line treatment with ii) front-line immunosuppressive therapy not followed by subsequent transplant given for failure and with iii) hematopoietic stem cell transplantation performed after failed front-line immunosuppressive therapy. Overall survival was 86% in the matched family donor hematopoietic stem cell transplantation group, 90% in patients given front-line immunosuppressive alone (those who did not fail this treatment and who did not receive subsequent rescue with hematopoietic stem cell transplantation) and 78% in subjects who underwent hematopoietic stem cell transplantation post failed front-line immunosuppressive therapy (P=0.14). Event-free survival in the same groups was respectively 83%, 64% and 71% (P=0.04). Cumulative incidence of rejection was 8% in matched family donor hematopoietic stem cell transplantation and 9% in transplants post failed front-line immunosuppression (P=0.62). Cumulative incidence of acute graft-versus-host disease was 12% in matched family donor transplants and 18% in transplants post failed immunosuppression (P=0.18). Chronic graft-versus-host disease was higher in matched family donor hematopoietic stem cell transplantation (8%) than in transplants post failed immunosuppressive therapy (20%) (P=0.0009). Cumulative incidence of post-therapy malignancies was 0.7% in matched family donor transplantations, 7% in transplantations post failed immunosuppression and 21% after front-line immunosuppression (P=0.0017). In the whole cohort, under multivariate analysis, the diagnosis to treatment interval of two months or under positively affected overall survival whereas up-front immunosuppression alone (with no subsequent rescue transplants) negatively affected event-free survival. In transplanted patients an interval from diagnosis to treatment of 2 months or under, bone marrow as source of cells and first-line matched family donor transplants provided a significant advantage in overall and event-free survival. Aplastic anemia in adolescents has a very good outcome. If a matched family donor is available, hematopoietic stem cell transplantation using bone marrow cells is the first choice treatment. If such a donor is not available, immunosuppressive treatment may still be an acceptable second choice, also because, in case of failure, hematopoietic stem cell transplantation is a very good rescue option., (Copyright© Ferrata Storti Foundation.)
- Published
- 2014
- Full Text
- View/download PDF
22. Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia: a report from the MDS Subcommittee of the Chronic Malignancies Working Party and the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation.
- Author
-
Hussein AA, Halkes CM, Socié G, Tichelli A, von dem Borne PA, Schaap MN, Foa R, Ganser A, Dufour C, Bacigalupo A, Locasciulli A, Aljurf M, Peters C, Robin M, van Biezen AA, Volin L, De Witte T, Marsh J, Passweg JR, and Kröger N
- Subjects
- Adolescent, Adult, Aged, Child, Child, Preschool, Europe, Female, Humans, Infant, Leukemia, Male, Middle Aged, Myelodysplastic Syndromes, Neoplasm Recurrence, Local, Treatment Outcome, Young Adult, Anemia, Aplastic therapy, Hematopoietic Stem Cell Transplantation adverse effects, Transplantation Conditioning adverse effects, Transplantation, Homologous adverse effects
- Abstract
One hundred and forty patients who had undergone hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) transformation after treatment of severe aplastic anemia (SAA) were identified in the European Group for Blood and Marrow Transplantation (EBMT) database. The median age at HSCT was 29 years (range, 1 to 66 years). The transplant donor was related in 49% cases and unrelated in 51% cases. The 5-year probability of relapse was 17%, and that of nonrelapse mortality was 41%. The 5-year overall survival was 45% ± 9%, better for patients untreated and patients in remission compared with patients with refractory disease. Our data indicate that allogeneic HSCT leads to prolonged survival in close to one-half of the patients transforming to MDS or AML from SAA., (Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
23. Outcome of patients activating an unrelated donor search for severe acquired aplastic anemia.
- Author
-
Maury S, Balère-Appert ML, Pollichieni S, Oneto R, Yakoub-Agha I, Locatelli F, Dalle JH, Lanino E, Fischer A, Pession A, Huynh A, Barberi W, Mohty M, Risitano A, Milpied N, Socié G, Bacigalupo A, Marsh J, and Passweg JR
- Subjects
- Adult, Age Factors, Child, Child, Preschool, Disease-Free Survival, Female, Histocompatibility Testing, Humans, Infant, Infant, Newborn, Male, Middle Aged, Retrospective Studies, Severity of Illness Index, Survival Rate, Transplantation, Homologous, Anemia, Aplastic mortality, Anemia, Aplastic therapy, Antilymphocyte Serum administration & dosage, Donor Selection, Hematopoietic Stem Cell Transplantation, Immunosuppressive Agents administration & dosage, Unrelated Donors
- Abstract
Patients with severe aplastic anemia (SAA) without a sibling donor receive immunosuppressive treatment (IST) with anti-thymocyte globulin (ATG). In the case of no response to IST, a voluntary unrelated donor (VUD) search is usually started. This study analyzes the outcome of ATG-refractory SAA patients activating a VUD search. Of 179 patients, 68 had at least one HLA-A, -B, and -DR matched donor identified and underwent HSCT while 50 also with a donor were not transplanted because of early death (8), late response to IST (34), transplant refusal (1), or other (7). Conversely, 61 had no matched donor, 13 of those ultimately received a mismatched HSCT. All but one received marrow stem cells. Among patients aged <17 years, those with at least one matched donor had a significant higher 4-year survival as compared to others (79% ± 6% versus 53% ± 10%, P = 0.01). There was also a survival advantage independent of recipient age when the donor search was initiated in the recent 2000-2005 study-period (74% ± 6% versus 47% ± 10%, P < 0.05). In multivariate analysis, the identification of a matched VUD tended to impact favourably on survival in patients with a recent donor search (P = 0.07). This study provides evidence for the use of unrelated donor HSCT in children and adults with IST-refractory SAA., (Copyright © 2013 Wiley Periodicals, Inc.)
- Published
- 2013
- Full Text
- View/download PDF
24. Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria.
- Author
-
Peffault de Latour R, Schrezenmeier H, Bacigalupo A, Blaise D, de Souza CA, Vigouroux S, Willemze R, Terriou L, Tichelli A, Mohty M, de Guibert S, Marsh JC, Passweg J, Yves Mary J, and Socié G
- Subjects
- Adult, Anemia, Aplastic etiology, Anemia, Hemolytic etiology, Female, Follow-Up Studies, Humans, Male, Survival Rate, Thromboembolism enzymology, Transplantation, Homologous, Anemia, Aplastic mortality, Anemia, Hemolytic mortality, Hemoglobinuria, Paroxysmal mortality, Hemoglobinuria, Paroxysmal therapy, Stem Cell Transplantation adverse effects, Thromboembolism mortality
- Abstract
Background: In the era of eculizumab, identifying patients with paroxysmal nocturnal hemoglobinuria who may benefit from allogeneic stem cell transplantation is challenging., Design and Methods: We describe the characteristics and overall survival of 211 patients transplanted for paroxysmal nocturnal hemoglobinuria in 83 EBMT centers from 1978 to 2007. Next, we conducted a comparison with a cohort of 402 non-transplanted patients with paroxysmal nocturnal hemoglobinuria diagnosed between 1950 and 2005 in 92 French centers. We compared the occurrence of complications (i.e. thromboembolism and aplastic anemia) using either an individual or a stratum-matching procedure., Results: After a median follow-up of 5 years, the 5-year overall survival rate ± standard error (%) was 68 ± 3 in the transplanted group (54 ± 7 in the case of thromboembolism, 69 ± 5 in the case of aplastic anemia without thromboembolism and 86 ± 6 in the case of recurrent hemolytic anemia without thromboembolism or aplastic anemia). Only thromboembolism as the indication for transplantation was associated with worse outcome (P=0.03). We identified 24 pairs of transplanted and non-transplanted patients with thromboembolism for the matched comparison, with worse overall survival for the transplanted patients (hazard ratio=10.0; 95% confidence interval, 1.3-78.1; P=0.007). This was confirmed by the global matching procedure (P=0.03). As regards aplastic anemia without thromboembolism, 30 pairs were identified for the matched comparison. It was not observed that transplanted patients had a significantly worse overall survival (hazard ratio=4.0; 95% confidence interval, 0.9-18.9; P=0.06). A global matching procedure was not feasible., Conclusions: Allogeneic stem cell transplantation is probably not a suitable treatment option for life-threatening thromboembolism in paroxysmal nocturnal hemoglobinuria.
- Published
- 2012
- Full Text
- View/download PDF
25. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups.
- Author
-
Bacigalupo A, Socié G, Schrezenmeier H, Tichelli A, Locasciulli A, Fuehrer M, Risitano AM, Dufour C, Passweg JR, Oneto R, Aljurf M, Flynn C, Mialou V, Hamladji RM, and Marsh JC
- Subjects
- Adolescent, Adult, Age Factors, Aged, Antilymphocyte Serum therapeutic use, Bone Marrow Transplantation adverse effects, Cause of Death, Child, Child, Preschool, Female, Graft Survival, Graft vs Host Disease etiology, Graft vs Host Disease therapy, Humans, Infant, Male, Middle Aged, Peripheral Blood Stem Cell Transplantation adverse effects, Transplantation, Homologous, Young Adult, Anemia, Aplastic mortality, Anemia, Aplastic therapy, Hematopoietic Stem Cell Transplantation adverse effects, Siblings
- Abstract
Background: Bone marrow has been shown to be superior to peripheral blood, as a stem cell source, in young patients (<20 years of age) with acquired aplastic anemia undergoing a matched sibling transplant. The aim of this study was to test whether this currently also holds true for older patients with acquired aplastic anemia., Design and Methods: We analyzed 1886 patients with acquired aplastic anemia who received a first transplant from a human leukocyte antigen identical sibling between 1999 and 2009, with either bone marrow (n=1163) or peripheral blood (n=723) as the source of stem cells., Results: In multivariate Cox analysis negative predictors for survival were: patient's age over 20 years (RR 2.0, P<0.0001), an interval between diagnosis and transplantation of more than 114 days (RR 1.3, P=0.006), no anti-thymocyte globulin in the conditioning (RR 1.6, P=0.0001), a conditioning regimen other than cyclophosphamide (RR=1.3, P=0.008) and the use of peripheral blood as the source of stem cells (RR 1.6, P<0.00001). The survival advantage for recipients of bone marrow rather than peripheral blood was statistically significant in patients aged 1-19 years (90% versus 76% P<0.00001) as well as in patients aged over 20 years (74% versus 64%, P=0.001). The advantage for recipients of bone marrow over peripheral blood was maintained above the age of 50 years (69% versus 39%, P=0.01). Acute and chronic graft-versus-host disease were more frequent in peripheral blood transplants. Major causes of death were graft-versus-host disease (2% versus 6% in bone marrow and peripheral blood recipients, respectively), infections (6% versus 13%), and graft rejection (1.5% versus 2.5%)., Conclusions: This study shows that bone marrow should be the preferred stem cell source for matched sibling transplants in acquired aplastic anemia, in patients of all age groups.
- Published
- 2012
- Full Text
- View/download PDF
26. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party.
- Author
-
Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano AM, Passweg JR, Killick SB, Warren AJ, Foukaneli T, Aljurf M, Al-Zahrani HA, Höchsmann B, Schafhausen P, Roth A, Franzke A, Brummendorf TH, Dufour C, Oneto R, Sedgwick P, Barrois A, Kordasti S, Elebute MO, Mufti GJ, and Socie G
- Subjects
- Adolescent, Adult, Aged, Animals, Antilymphocyte Serum adverse effects, CD4-Positive T-Lymphocytes drug effects, Cyclosporine adverse effects, Drug Therapy, Combination, Europe, Female, Horses, Humans, Immunosuppressive Agents adverse effects, Male, Middle Aged, Pilot Projects, Prospective Studies, Rabbits, Survival Analysis, Young Adult, Anemia, Aplastic drug therapy, Antilymphocyte Serum therapeutic use, Cyclosporine therapeutic use, Immunosuppressive Agents therapeutic use
- Abstract
Rabbit antithymocyte globulin (rATG; thymoglobulin, Genzyme) in combination with cyclosporine, as first-line immunosuppressive therapy, was evaluated prospectively in a multicenter, European, phase 2 pilot study, in 35 patients with aplastic anemia. Results were compared with 105 age- and disease severity-matched patients from the European Blood and Marrow Transplant registry, treated with horse ATG (hATG; lymphoglobulin) and cyclosporine. The primary end point was response at 6 months. At 3 months, no patients had achieved a complete response to rATG. Partial response occurred in 11 (34%). At 6 months, complete response rate was 3% and partial response rate 37%. There were 10 deaths after rATG (28.5%) and 1 after subsequent HSCT. Infections were the main cause of death in 9 of 10 patients. The best response rate was 60% for rATG and 67% for hATG. For rATG, overall survival at 2 years was 68%, compared with 86% for hATG (P = .009). Transplant-free survival was 52% for rATG and 76% for hATG (P = .002). On multivariate analysis, rATG (hazard ratio = 3.9, P = .003) and age more than 37 years (hazard ratio = 4.7, P = .0008) were independent adverse risk factors for survival. This study was registered at www.clinicaltrials.gov as NCT00471848.
- Published
- 2012
- Full Text
- View/download PDF
27. The Third Consensus Conference on the treatment of aplastic anemia.
- Author
-
Kojima S, Nakao S, Young N, Bacigalupo A, Gerard G, Hirano N, Maciejewski J, Deeg J, Marsh J, Zhang FK, Lee JW, and Ozawa K
- Subjects
- Anemia, Aplastic diagnosis, Anemia, Aplastic drug therapy, Anemia, Aplastic genetics, Humans, Anemia, Aplastic therapy, Immunosuppressive Agents therapeutic use, Stem Cell Transplantation
- Published
- 2011
- Full Text
- View/download PDF
28. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation.
- Author
-
Tichelli A, Schrezenmeier H, Socié G, Marsh J, Bacigalupo A, Dührsen U, Franzke A, Hallek M, Thiel E, Wilhelm M, Höchsmann B, Barrois A, Champion K, and Passweg JR
- Subjects
- Adolescent, Adult, Anemia, Aplastic diagnosis, Anemia, Aplastic mortality, Child, Child, Preschool, Disease-Free Survival, Drug Therapy, Combination, Female, Hospitalization statistics & numerical data, Humans, Male, Middle Aged, Severity of Illness Index, Survival Analysis, Young Adult, Anemia, Aplastic drug therapy, Antilymphocyte Serum administration & dosage, Cyclosporine administration & dosage, Granulocyte Colony-Stimulating Factor administration & dosage, Immunosuppressive Agents administration & dosage
- Abstract
We evaluated the role of granulocyte colony-stimulating factor (G-CSF) in patients with severe aplastic anemia (SAA) treated with antithymocyte globulin (ATG) and cyclosporine (CSA). Between January 2002 and July 2008, 192 patients with newly diagnosed SAA not eligible for transplantation were entered into this multicenter, randomized study to receive ATG/CSA with or without G-CSF. Overall survival (OS) at 6 years was 76% ± 4%, and event-free survival (EFS) was 42% ± 4%. No difference in OS/EFS was seen between patients randomly assigned to receive or not to receive G-CSF, neither for the entire cohort nor in subgroups stratified by age and disease severity. Patients treated with G-CSF had fewer infectious episodes (24%) and hospitalization days (82%) compared with patients without G-CSF (36%; P = .006; 87%; P = .0003). In a post hoc analysis of patients receiving G-CSF, the lack of a neutrophil response by day 30 was associated with significantly lower response rate (56% vs 81%; P = .048) and survival (65% vs 87%; P = .031). G-CSF added to standard ATG and CSA reduces the rate of early infectious episodes and days of hospitalization in very SAA patients and might allow early identification of nonresponders but has no effect on OS, EFS, remission, relapse rates, and mortality. This study was registered at www.clinicaltrials.gov as NCT01163942.
- Published
- 2011
- Full Text
- View/download PDF
29. Should irradiated blood products be given routinely to all patients with aplastic anaemia undergoing immunosuppressive therapy with antithymocyte globulin (ATG)? A survey from the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party.
- Author
-
Marsh J, Socie G, Tichelli A, Schrezenmeier H, Hochsmann B, Risitano AM, Fuehrer M, Bekassy AN, Korthof ET, Locasciulli A, Ljungman P, Bacigalupo A, Camitta B, Young NS, and Passweg J
- Subjects
- Blood radiation effects, Bone Marrow Transplantation, Graft vs Host Disease prevention & control, Health Care Surveys, Humans, Anemia, Aplastic therapy, Antilymphocyte Serum therapeutic use, Blood Component Transfusion statistics & numerical data, Immunosuppressive Agents therapeutic use
- Published
- 2010
- Full Text
- View/download PDF
30. Hepatitis-associated aplastic anaemia: epidemiology and treatment results obtained in Europe. A report of The EBMT aplastic anaemia working party.
- Author
-
Locasciulli A, Bacigalupo A, Bruno B, Montante B, Marsh J, Tichelli A, Socié G, and Passweg J
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Anemia, Aplastic epidemiology, Anemia, Aplastic therapy, Bone Marrow Transplantation, Child, Child, Preschool, Epidemiologic Methods, Europe epidemiology, Female, Hepatitis epidemiology, Humans, Immunosuppressive Agents therapeutic use, Infant, Male, Middle Aged, Treatment Outcome, Young Adult, Anemia, Aplastic etiology, Hepatitis complications
- Abstract
In order to assess the epidemiology of Hepatitis-Associated Aplasia (HAA) and compare treatment outcome of HAA with non-HAA patients, we evaluated 3916 aplastic anaemia patients reported to the European Registry between 1990 and 2007. Year, month, season of diagnosis, type and outcome of first-line therapy were analysed. Prevalence of HAA (n = 214) in Europe was 5%. Compared to non-HAA patients, HAA patients were younger (15 vs. 20 years, P < 0.001), with a male prevalence (68% vs. 58% P = 0.002), and were treated earlier after diagnosis (46 vs. 62 d; P < 0.001). No significant differences were found regarding the year or month of diagnosis. No geographic clusters could be identified. Actuarial survival at 10 years after first-line immunosuppression was 69%, and did not differ according to aetiology. The 10-year actuarial survival after transplantation was 70%, and was comparable in HAA and non-HAA patients, when stratified for age and donor type. In a multivariate Cox analysis, increasing age and delayed treatment were significant negative indicators for survival. In conclusion, the incidence of HAA was 5% and was evenly distributed over time and geographic areas in Europe. Treatment outcome and predictive variables, were comparable in patients with or without HAA.
- Published
- 2010
- Full Text
- View/download PDF
31. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party.
- Author
-
Bacigalupo A, Socie' G, Lanino E, Prete A, Locatelli F, Locasciulli A, Cesaro S, Shimoni A, Marsh J, Brune M, Van Lint MT, Oneto R, and Passweg J
- Subjects
- Adolescent, Adult, Anemia, Aplastic drug therapy, Anemia, Aplastic mortality, Child, Child, Preschool, Europe, Female, Follow-Up Studies, Graft vs Host Disease drug therapy, Graft vs Host Disease mortality, Graft vs Host Disease prevention & control, Humans, Living Donors, Male, Middle Aged, Retrospective Studies, Survival Rate trends, Transplantation Conditioning methods, Vidarabine therapeutic use, Whole-Body Irradiation methods, Young Adult, Anemia, Aplastic surgery, Antilymphocyte Serum therapeutic use, Bone Marrow Transplantation methods, Cyclophosphamide therapeutic use, Hematopoietic Stem Cell Transplantation methods, Vidarabine analogs & derivatives
- Abstract
Background: We analyzed the outcome of 100 patients with acquired severe aplastic anemia undergoing an alternative donor transplant, after immune suppressive therapy had failed., Design and Methods: As a conditioning regimen, patients received either a combination of fludarabine, cyclophosphamide, and antithymocyte globulin (n=52, median age 13 years) or this combination with the addition of low dose (2 Gy) total body irradiation (n=48, median age 27 years)., Results: With a median follow-up of 1665 and 765 days, the actuarial 5-year survival was 73% for the group that received fludarabine, cyclophosphamide, and antithymocyte globulin and 79% for the group given the conditioning regimen including total body irradiation. Acute graft-versus-host disease grade III-IV was seen in 18% and 7% of the groups, respectively. Graft failure was seen in 17 patients with an overall cumulative incidence of 17% in patients receiving conditioning with or without total body irradiation: 9 of these 17 patients survive in the long-term. The most significant predictor of survival was the interval between diagnosis and transplantation, with 5-year survival rates of 87% and 55% for patients grafted within 2 years of diagnosis and more than 2 years after diagnosis, respectively (P=0.0004). Major causes of death were graft failure (n=7), post-transplant-lymphoproliferative-disease (n=4) and graft-versus-host disease (n=4)., Conclusions: This study confirms positive results of alternative donor transplants in patients with severe aplastic anemia, the best outcomes being achieved in patients grafted within 2 years of diagnosis. Prevention of rejection and Epstein-Barr virus reactivation may further improve these results.
- Published
- 2010
- Full Text
- View/download PDF
32. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA.
- Author
-
Risitano AM, Selleri C, Serio B, Torelli GF, Kulagin A, Maury S, Halter J, Gupta V, Bacigalupo A, Sociè G, Tichelli A, Schrezenmeier H, Marsh J, Passweg J, and Rotoli B
- Subjects
- Adult, Aged, Aged, 80 and over, Alemtuzumab, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized, Antibodies, Neoplasm adverse effects, Cyclosporine therapeutic use, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents adverse effects, Injections, Subcutaneous, Male, Middle Aged, Pilot Projects, Prospective Studies, Anemia, Aplastic drug therapy, Antibodies, Monoclonal therapeutic use, Antibodies, Neoplasm therapeutic use, Immunosuppressive Agents therapeutic use
- Abstract
An alemtuzumab-based experimental immunosuppressive treatment (IST) regimen was investigated in 35 patients with severe aplastic anaemia (SAA), pure red cell (PRCA) or pure white cell aplasia (PWCA). Alemtuzumab total dose was 73-103 mg s.c., followed by cyclosporine. No serious toxicity due to the regimen was observed. Adverse events were clinically irrelevant; infectious events were rare. The total response rate was 58%, 84% and 100% in SAA, PRCA and PWCA, respectively, with corresponding 6 months cumulative response probabilities of 84%, 84% and 100%. Subcutaneous alemtuzumab is a feasible and sufficiently safe IST regimen for patients suffering from immune-mediated marrow failures.
- Published
- 2010
- Full Text
- View/download PDF
33. Aplastic anemia: pathophysiology and treatment.
- Author
-
Young NS, Bacigalupo A, and Marsh JC
- Subjects
- Anemia, Aplastic complications, Anemia, Aplastic genetics, Anemia, Aplastic physiopathology, Bone Marrow Transplantation immunology, Bone Marrow Transplantation methods, Cord Blood Stem Cell Transplantation methods, Humans, Immunosuppressive Agents therapeutic use, Anemia, Aplastic etiology, Anemia, Aplastic therapy
- Abstract
An immune basis for most patients with aplastic anemia (AA) provides a rationale for immunosuppressive therapy (IST), using antithmyocyte globulin and cyclosporine as one therapeutic modality; hematologic response is observed in up to 75% of patients. Recent advances in understanding the pathogenesis of AA have identified defective telomere maintenance as an important explanation for the onset of marrow failure, relapse and clonal evolution after IST, in some patients with AA. The finding of inherited mutations in the telomerase gene complex in patients with apparent acquired AA has important implications for clinical management. Hematopoietic stem cell transplantation (HSCT) for acquired AA, whether from an HLA identical sibling or an unrelated donor, provides an excellent chance of long term cure. Current issues with HSCT include graft rejection, chronic GVHD and poor outcome in older patients. The lack of a suitable bone marrow donor for all patients who need a transplant, illustrates the need for novel transplant procedures, such as cord blood transplantation., (Copyright 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
34. Changes in cytokine profile pre- and post-immunosuppression in acquired aplastic anemia.
- Author
-
Dufour C, Ferretti E, Bagnasco F, Burlando O, Lanciotti M, Ramenghi U, Saracco P, Van Lint MT, Longoni D, Torelli GF, Pillon M, Locasciulli A, Misuraca A, La Spina M, Bacigalupo A, Pistoia V, Corcione A, and Svahn J
- Subjects
- Adolescent, Adult, Anemia, Aplastic pathology, Bone Marrow Cells metabolism, Bone Marrow Cells pathology, CD3 Complex metabolism, Cell Proliferation, Cells, Cultured, Child, Child, Preschool, Female, Flow Cytometry, Humans, Male, Middle Aged, Time Factors, Young Adult, Anemia, Aplastic metabolism, Immunosuppression Therapy methods, Interferon-gamma metabolism, Interleukin-4 metabolism, Tumor Necrosis Factor-alpha metabolism
- Abstract
Cytokine expression assessed by flow cytometry in 53 acquired aplastic anemia patients before and after combined immunosuppression (EBMT WPSAA protocols) showed that CD3(+) marrow cells containing TNF-alpha, IFN-gamma and IL4 were similar in subjects with disease at onset (DO) and responsive to treatment who had more CD3(+)/TNF-alpha(+) and CD 3(+)/IFN-gamma(+) cells than normal controls. In vitro block of TNF-alpha and/or IFN-gamma significantly increased BFU-e over baseline in 28 patients. In responsive to treatment patients only TNF-alpha block significantly incremented colonies over normal controls. Absolute marrow CD3(+)/TNF-alpha(+) and CD3(+)/IFN-gamma(+) cells prospectively tested in a group of 21 subjects declined significantly more in Responders than in Non Responders to immunosuppression at Response Evaluation Time respect to Diagnosis. Both in Responders and in Non Responders these cells remained higher than in normal controls. This study suggests that immunosuppression does not fully clear excess TNF-alpha and IFN-gamma from marrow of patients with good outcome and raises the hypothesis that additional cytokine blockade might be useful in immunosuppression for acquired aplastic anemia.
- Published
- 2009
- Full Text
- View/download PDF
35. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen.
- Author
-
Maury S, Bacigalupo A, Anderlini P, Aljurf M, Marsh J, Socié G, Oneto R, and Passweg JR
- Subjects
- Adult, Aged, Anemia, Aplastic mortality, Antilymphocyte Serum administration & dosage, Cyclophosphamide administration & dosage, Disease-Free Survival, Female, Follow-Up Studies, HLA Antigens, Humans, Immunosuppressive Agents administration & dosage, Male, Middle Aged, Retrospective Studies, Survival Rate, Transplantation, Homologous, Vidarabine administration & dosage, Anemia, Aplastic therapy, Hematopoietic Stem Cell Transplantation, Living Donors, Myeloablative Agonists administration & dosage, Siblings, Transplantation Conditioning methods, Vidarabine analogs & derivatives
- Abstract
Older age is a limitation for HLA-identical sibling hematopoietic stem cell transplantation (HSCT) as first-line therapy for severe acquired idiopathic aplastic anemia (SAA). Fludarabine (Flu)-based conditioning might improve outcome in older patients. We analyzed retrospectively 30 patients older than 30 years receiving such reduced-intensity conditioning HSCT according to recommendations of the European Group for Blood and Marrow Transplantation (EBMT) and compared their outcome to a control group receiving the standard regimen (cyclophosphamide+/-antithymocyte globulin) over the same study period (1998-2007). Patients conditioned with Flu had a higher probability of overall survival than the control group (p=0.04) when adjusting for recipient's age. This might be related to a trend towards a reduced incidence of graft failure in patients receiving Flu (0% vs. 11%, p=0.09), while no difference was observed regarding graft-versus-host disease incidence. Flu-based conditioning regimen may reduce the negative impact of age in older patients with SAA receiving an HLA-identical sibling HSCT.
- Published
- 2009
- Full Text
- View/download PDF
36. Diagnosis and treatment of acquired aplastic anemia.
- Author
-
Bacigalupo A and Passweg J
- Subjects
- Age Factors, Anemia, Aplastic drug therapy, Animals, Bone Marrow Transplantation mortality, Female, Fetal Blood transplantation, Humans, Male, Pregnancy, Prognosis, Anemia, Aplastic diagnosis, Anemia, Aplastic therapy, Antilymphocyte Serum therapeutic use, Bone Marrow Transplantation immunology, Cyclosporine therapeutic use, Immunosuppressive Agents therapeutic use, Intercellular Signaling Peptides and Proteins therapeutic use
- Abstract
Acquired severe aplastic anemia can be treated successfully with either immunosuppressive therapy or bone marrow transplantation. Although immunosuppressive therapy can be readily administered to all patients, it is not a curative approach and is associated with a higher risk of clonal evolution than is transplantation, which yields rapid and long-lasting hematologic remission. This article reviews the key diagnostic and prognostic factors that influence the choice of therapy in patients with acquired aplastic anemia.
- Published
- 2009
- Full Text
- View/download PDF
37. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA.
- Author
-
Lawler M, McCann SR, Marsh JC, Ljungman P, Hows J, Vandenberghe E, O'Riordan J, Locasciulli A, Socié G, Kelly A, Schrezenmeier H, Marin P, Tichelli A, Passweg JR, Dickenson A, Ryan J, and Bacigalupo A
- Subjects
- Adolescent, Adult, Anemia, Aplastic genetics, Anemia, Aplastic mortality, Child, Child, Preschool, Chimerism, Cyclosporine therapeutic use, Fanconi Anemia genetics, Fanconi Anemia mortality, Fanconi Anemia therapy, Female, Follow-Up Studies, Humans, Immunosuppressive Agents therapeutic use, Male, Middle Aged, Polymerase Chain Reaction methods, Prognosis, Proportional Hazards Models, Recurrence, Survival Rate, Tandem Repeat Sequences, Time Factors, Transplantation Conditioning, Transplantation, Homologous, Young Adult, Anemia, Aplastic therapy, Graft Rejection, Stem Cell Transplantation adverse effects
- Abstract
Ninety-one patients were studied serially for chimeric status following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA) or Fanconi Anaemia (FA). Short tandem repeat polymerase chain reaction (STR-PCR) was used to stratify patients into five groups: (A) complete donor chimeras (n = 39), (B) transient mixed chimeras (n = 15) (C) stable mixed chimeras (n = 18), (D) progressive mixed chimeras (n = 14) (E) recipient chimeras with early graft rejection (n = 5). As serial sampling was not possible in Group E, serial chimerism results for 86 patients were available for analysis. The following factors were analysed for association with chimeric status: age, sex match, donor type, aetiology of aplasia, source of stem cells, number of cells engrafted, conditioning regimen, graft-versus-host disease (GvHD) prophylaxis, occurrence of acute and chronic GvHD and survival. Progressive mixed chimeras (PMCs) were at high risk of late graft rejection (n = 10, P < 0.0001). Seven of these patients lost their graft during withdrawal of immunosuppressive therapy. STR-PCR indicated an inverse correlation between detection of recipient cells post-SCT and occurrence of acute GvHD (P = 0.008). PMC was a bad prognostic indicator of survival (P = 0.003). Monitoring of chimeric status during cyclosporin withdrawal may facilitate therapeutic intervention to prevent late graft rejection in patients transplanted for SAA.
- Published
- 2009
- Full Text
- View/download PDF
38. Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up.
- Author
-
Saracco P, Quarello P, Iori AP, Zecca M, Longoni D, Svahn J, Varotto S, Del Vecchio GC, Dufour C, Ramenghi U, Bacigalupo A, and Locasciulli A
- Subjects
- Adolescent, Anemia, Aplastic blood, Child, Child, Preschool, Cyclosporine administration & dosage, Cyclosporine blood, Disease Progression, Drug Administration Schedule, Drug Evaluation, Drug Therapy, Combination, Epidemiologic Methods, Female, Granulocyte Colony-Stimulating Factor administration & dosage, Granulocyte Colony-Stimulating Factor therapeutic use, Humans, Immunosuppressive Agents administration & dosage, Immunosuppressive Agents blood, Infant, Male, Recurrence, Treatment Outcome, Anemia, Aplastic drug therapy, Cyclosporine therapeutic use, Immunosuppressive Agents therapeutic use
- Abstract
Immunosuppressive therapy (IST) with antithymocyte globulin and cyclosporin A (CyA) is the standard treatment for children with acquired aplastic anaemia (AAA) lacking a matched donor. Survival rates of more than 80% at 5 years are achieved, but the response is drug-dependent in 15-25% of cases. This study, of 42 consecutive children with AAA treated with IST, assessed the incidence of CyA-dependence, CyA and granulocyte colony-stimulating factor (G-CSF) tapering schedules and the impact of drug accumulation on progression to myelodysplasia/acute myeloid leukaemia (MDS/AML). Overall survival was 83% at 10 years. CyA-dependence without a predictive marker was observed in 18% of responders. Probability of discontinuing CyA was 60.5% at 10 years; a slow CyA tapering schedule was performed in 84% of patients; the cumulative incidence of relapse was 16% at 10 years. Relapse risk was significantly associated with rapid CyA discontinuation: 60% compared to 7.6% in the slow tapering group (P = 0.001). Cumulative incidence of MDS/AML was 8% at 10 years, with a significant correlation with both G-CSF cumulative dose and second IST. This long-term follow-up of children with AAA shows that IST with a slow CyA tapering course is an effective treatment with a low-relapse rate in these cases.
- Published
- 2008
- Full Text
- View/download PDF
39. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia.
- Author
-
Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN, Bullorsky E, Camitta BM, Champlin RE, Gale RP, Fuhrer M, Klein JP, Locasciulli A, Oneto R, Schattenberg AV, Socie G, and Eapen M
- Subjects
- Adult, Female, HLA Antigens, Humans, Male, Siblings, Survival Rate, Tissue Donors, Transplantation, Homologous, Treatment Outcome, Anemia, Aplastic therapy, Bone Marrow Transplantation, Graft vs Host Disease etiology, Peripheral Blood Stem Cell Transplantation
- Abstract
We analyzed the outcome of 692 patients with severe aplastic anemia (SAA) receiving transplants from HLA-matched siblings. A total of 134 grafts were peripheral blood progenitor cell (PBPC) grafts, and 558 were bone marrow (BM) grafts. Rates of hematopoietic recovery and grades 2 to 4 chronic graft-versus-host disease (GVHD) were similar after PBPC and BM transplantations regardless of age at transplantation. In patients older than 20 years, chronic GVHD and overall mortality rates were similar after PBPC and BM transplantations. In patients younger than 20 years, rates of chronic GVHD (relative risk [RR] 2.82; P = .002) and overall mortality (RR 2.04; P = .024) were higher after transplantation of PBPCs than after transplantation of BM. In younger patients, the 5-year probabilities of overall survival were 73% and 85% after PBPC and BM transplantations, respectively. Corresponding probabilities for older patients were 52% and 64%. These data indicate that BM grafts are preferred to PBPC grafts in young patients undergoing HLA-matched sibling donor transplantation for SAA.
- Published
- 2007
- Full Text
- View/download PDF
40. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT).
- Author
-
Socie G, Mary JY, Schrezenmeier H, Marsh J, Bacigalupo A, Locasciulli A, Fuehrer M, Bekassy A, Tichelli A, and Passweg J
- Subjects
- Adolescent, Adult, Anemia, Aplastic complications, Antilymphocyte Serum administration & dosage, Cyclosporine administration & dosage, Data Collection, Europe, Female, Granulocyte Colony-Stimulating Factor administration & dosage, Humans, Immunosuppressive Agents administration & dosage, Male, Middle Aged, Recombinant Proteins, Risk Factors, Anemia, Aplastic drug therapy, Granulocyte Colony-Stimulating Factor adverse effects, Myelodysplastic Syndromes etiology
- Abstract
Previous studies suggested a link between the use of G-CSF and increased incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) after immunosuppressive therapy (IST) for severe aplastic anemia (SAA). This European survey included 840 patients who received a first-line IST with (43%) or without (57%) G-CSF. The incidences of MDS/AML in patients who did or did not receive G-CSF were 10.9% and 5.8%, respectively. A significantly higher hazard (1.9) of MDS/AML was associated with use of G-CSF. Relapse of aplastic anemia was not associated with a worse outcome in patients who did not receive G-CSF as first therapy, whereas relapse was associated with a significantly worse outcome in those patients who received G-CSF. These results emphasize the necessity of the current European randomized trial comparing IST with or without G-CSF and to alert physicians that adding G-CSF to IST is currently not standard treatment for SAA.
- Published
- 2007
- Full Text
- View/download PDF
41. Aplastic anemia: pathogenesis and treatment.
- Author
-
Bacigalupo A
- Subjects
- Anemia, Aplastic drug therapy, Anemia, Aplastic surgery, Bone Marrow Transplantation, Humans, Immunosuppressive Agents administration & dosage, Anemia, Aplastic etiology, Anemia, Aplastic therapy
- Abstract
This review highlights some of the contributions that have appeared in the literature in the past decade on the pathogenesis and treatment of aplastic anemia (AA). This summary is brief because the field is vast, spaning from stem cell biology to stem cell disorders, from autoimmunity to transplantation, from graft-versus-host disease to late effects. The immune pathogenesis of AA is now based on several lines of evidence and will be discussed. Immunosuppressive therapy (IST) remains an important option for AA patients who are not candidates for transplantation. Favorable prognostic indicators for IST are young age and a short interval from diagnosis; the neutrophil count seems to have lost its predictive value with current antithymocyte globulin-cyclsoporin combination therapy. The outcome of allogeneic bone marrow transplantations has significantly improved in the past decade, particularly in the unrelated donor setting, to such an extent that treatment strategies may be affected. A short interval between diagnosis and treatment will also improve results for bone marrow transplantation; these rare patients should be referred to an experienced center immediately.
- Published
- 2007
- Full Text
- View/download PDF
42. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT).
- Author
-
Locasciulli A, Oneto R, Bacigalupo A, Socié G, Korthof E, Bekassy A, Schrezenmeier H, Passweg J, and Führer M
- Subjects
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Child, Child, Preschool, Cohort Studies, Europe, Family Health, Humans, Infant, Middle Aged, Retrospective Studies, Transplantation Conditioning, Transplantation, Homologous, Anemia, Aplastic therapy, Bone Marrow Transplantation methods, Immunosuppressive Agents therapeutic use
- Abstract
Background and Objectives: The treatment of acquired aplastic anemia (AA) is based on allogeneic bone marrow transplantation (BMT) and immunosuppressive therapy. The aim of this study was to assess the outcome of children and adults with AA treated in the last decade, and to determine whether results have improved in two sequential time periods,1991-1996 and 1997-2002., Design and Methods: Two-thousands and seventy-nine consecutive patients with AA, classified according to first-line treatment: BMT (n=1567) or immunosuppressive therapy (n= 912), the patients for the two sequential time periods were studied. Analyses included variables related to patients, disease and transplant., Results: The actuarial 10-year survival was 73% and 68% for BMT or immunosuppressive treatment, respectively (p=0.002). BMT outcome improved significantly with time (69% and 77%, p=001) for both matched sibling donor (MSD) (74% and 80%; p=0.003 ), alternative donor (38% and 65% p=0.0001), and was better in children (79% versus 68%, p<0.0001). Multivariate analysis: favorable predictors (p<0.001) were younger age, transplant beyond 1996, MSD, a short interval diagnosis-transplant , no irradiation. IS: no significant improvement over time (69% and 73% p=0.29). Survival was significantly better in children (81% versus 70%, p=0.001), especially in vSAA(83% versus 62%, p=0.0002). Combined IS was superior to single drug treatment (77% versus 62%, p=0.002). Multivariate analysis: significant predictors of survival: age > or =16 years (p=0.0009), longer interval between diagnosis -treatment (p=0.04), single drug versus combined IS (p=0.02)., Interpretation and Conclusions: Outcome has improved in subsets of AA patients: those receiving first- line BMT and children with vSAA treated with IS. Age remains a major predictor for both treatments. Early intervention is associated with a significantly better outcome and is strongly recommended, whatever the first-line therapy.
- Published
- 2007
- Full Text
- View/download PDF
43. Influence of donor/recipient sex matching on outcome of allogeneic hematopoietic stem cell transplantation for aplastic anemia.
- Author
-
Stern M, Passweg JR, Locasciulli A, Socié G, Schrezenmeier H, Békássy AN, Fuehrer M, Hows J, Korthof ET, McCann S, Tichelli A, Zoumbos NC, Marsh JC, Bacigalupo A, and Gratwohl A
- Subjects
- Adolescent, Adult, Child, Cohort Studies, Female, Graft vs Host Disease epidemiology, Histocompatibility Testing, Humans, Male, Retrospective Studies, Sex Factors, Stem Cell Transplantation adverse effects, Stem Cell Transplantation mortality, Survival Analysis, Time Factors, Transplantation, Homologous, Treatment Outcome, Anemia, Aplastic therapy, Stem Cell Transplantation methods
- Abstract
Background: Increased risk of transplant related mortality in male recipients of female hematopoietic stem cell grafts and in vitro reactivity of lymphocytes against H-Y encoded gene products in females with rejected male grafts have been documented. An increased rejection of male grafts in female recipients is not reported for solid organ or stem cell transplants and the role of H-Y as transplantation antigen has been controversial., Methods: Data from 1481 patients with a hematopoietic stem cell transplant for aplastic anemia reported from 154 centers in 28 countries were analyzed. Outcome was compared between patients with donors of the same or opposite sex., Results: Survival at 5 years was significantly better in patients with donors from the same sex: 68% vs. 60% (P = 0.001). Male patients with female donors had a decreased survival (relative risk of death 1.52, P < 0.001) and an increased risk of severe graft-versus-host disease (relative risk 1.33, P = 0.03) compared to recipients of sex-matched grafts. Female patients with male donors had a decreased survival (relative risk of death 1.44, P = 0.01) and an increased risk of rejection (relative risk 2.20, P = 0.01) compared to recipients of sex-matched grafts. In a subgroup analysis, the negative effects of donor/recipient sex-mismatching appeared confined to patients receiving conditioning regimens not containing antithymocyte globulin., Conclusions: These data confirm H-Y as a clinically relevant transplantation antigen, in both the graft-versus-host and the host-versus-graft direction. Wherever possible, donor-recipient sex-matching should be integrated into donor selection algorithms.
- Published
- 2006
- Full Text
- View/download PDF
44. Aplastic anemia.
- Author
-
Kojima S, Frickhofen N, Deeg HJ, Okamoto S, Marsh J, Teramura M, Bacigalupo A, and Mizoguchi H
- Subjects
- Anemia, Aplastic immunology, Anemia, Aplastic pathology, Hematopoietic Stem Cells pathology, Humans, Immunosuppression Therapy methods, Mesenchymal Stem Cells pathology, Pancytopenia immunology, Pancytopenia pathology, Pancytopenia therapy, T-Lymphocytes immunology, T-Lymphocytes pathology, Anemia, Aplastic therapy, Hematopoietic Stem Cells immunology, Mesenchymal Stem Cells immunology
- Published
- 2005
- Full Text
- View/download PDF
45. Genetic polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 and the risk of acquired idiopathic aplastic anemia in Caucasian patients.
- Author
-
Dufour C, Svahn J, Bacigalupo A, Longoni D, Varotto S, Iori AP, Bagnasco F, Locasciulli A, Menna G, Ramenghi U, and Lanciotti M
- Subjects
- Adolescent, Adult, Anemia, Aplastic epidemiology, Child, Child, Preschool, Cytochrome P-450 CYP3A, Female, Genotype, Humans, Infant, Male, Middle Aged, Reference Values, White People genetics, Anemia, Aplastic genetics, Cytochrome P-450 Enzyme System genetics, Glutathione S-Transferase pi genetics, Glutathione Transferase genetics, NAD(P)H Dehydrogenase (Quinone) genetics, Polymorphism, Genetic
- Abstract
Background and Objectives: Various drugs and xenobiotics are involved in the pathogenesis of acquired aplastic anemia. Their harmful potential depends on the amount of exposure to them and on the detoxifying capacity of the recipient. Genetic polymorphisms of some important detoxifying enzymes are associated with low or absent cata-lytic activity of the protein. We assessed whether, in a Caucasian population, low or null activity polymorphisms of CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 were associated with the risk of developing aplastic anemia and with the response to immunosuppressive therapy., Design and Methods: In 77 Caucasian patients with aplastic anemia and in 156 normal controls we evaluated the distribution of the following polymorphisms which are associated with low or no activity of the corresponding enzyme: (i)-290 A-->G of the CYP3A4 gene, deletions of (ii) GSTT1 and (iii) GSTM1 genes, (iv) 313A-->G of the GSTP1 gene and (v) 609 C-->T of the NQO1 gene., Results: The distribution of the genotypes of all tested polymorphisms was not different in patients and controls. No differences were seen among the patients when the group was subdivided by age and severity of the disease. Only the GSTM1 null genotype was significantly more frequent in male patients than in male controls. The frequency of all tested polymorphisms did not differ in patients who did or did not respond to immunosuppressive therapy., Interpretation and Conclusions: The low/null activity polymorphisms of the detoxifying enzymes CYP3A4, GSTT1, GSTM1, GSTP1 and NQO1 are not associated with the risk of developing aplastic anemia or to the response to immunosuppressive therapy in Caucasian patients.
- Published
- 2005
46. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia.
- Author
-
Bacigalupo A, Valle M, Podestà M, Pitto A, Zocchi E, De Flora A, Pozzi S, Luchetti S, Frassoni F, Van Lint MT, and Piaggio G
- Subjects
- Adolescent, Adult, Aged, Bone Marrow Cells cytology, Bone Marrow Cells pathology, Bone Marrow Transplantation immunology, Female, Humans, Immunosuppression Therapy, Lymphocyte Activation, Lymphocyte Culture Test, Mixed, Male, Middle Aged, Phytohemagglutinins, Reference Values, Anemia, Aplastic immunology, Anemia, Aplastic pathology, Mesoderm physiology, Stem Cells physiology, T-Lymphocytes immunology
- Abstract
Objective: To compare the suppressive effect of mesenchymal stem cells (MSC), derived from normal individuals or severe aplastic anemia patients (SAA), on T-cell activation., Patients and Methods: We studied bone marrow MSC from 19 healthy donors and 23 SAA patients in different phases of the disease: at diagnosis (n = 3), following immunosuppressive therapy (IS) (n = 16), or after a bone marrow transplant (BMT) (n = 4). MSC were tested for T-cell suppression in the following assays: mixed lymphocyte reaction (MLR), phytohemaglutinin (PHA)-primed cultures, activation surface markers, gamma-IFN production, hematopoietic colony formation (CFC), production of cyclic ADP-ribose (cADPR)., Results: The abnormalities of SAA MSC included: 1) significantly lower suppression of T-cell proliferation induced by alloantigens (p = 0.009) or PHA (p = 0.006); 2) impaired capacity to suppress CD38 expression on PHA-primed T cells (p = 0.001); 3) impaired ability to suppress gamma-IFN production in PHA cultures, resulting in an 11-fold higher gamma-IFN concentration; 4) no preventive effect on T cell-mediated inhibition of CFC; and 5) significantly reduced (p = 0.009) production of cADPR, a universal calcium mobilizer. MSC-mediated suppression of PHA-induced T-cell proliferation was restored to control levels in 3 of 4 patients post-BMT., Conclusion: The ability of MSC to downregulate T-cell priming, proliferation, and cytokine release is deficient in patients with SAA, persists indefinitely after immunosuppressive therapy, but seems to be restored after BMT. Whether these abnormalities are relevant to the pathogenesis of aplastic anemia remains to be determined.
- Published
- 2005
- Full Text
- View/download PDF
47. Homozygosis for (12) CA repeats in the first intron of the human IFN-gamma gene is significantly associated with the risk of aplastic anaemia in Caucasian population.
- Author
-
Dufour C, Capasso M, Svahn J, Marrone A, Haupt R, Bacigalupo A, Giordani L, Longoni D, Pillon M, Pistorio A, Di Michele P, Iori AP, Pongiglione C, Lanciotti M, and Iolascon A
- Subjects
- Adolescent, Adult, Anemia, Aplastic immunology, Case-Control Studies, Child, Child, Preschool, Female, Homozygote, Humans, Infant, Introns, Male, Risk, White People, Anemia, Aplastic genetics, Dinucleotide Repeats, Interferon-gamma genetics, Polymorphism, Genetic
- Abstract
Interferon-gamma (IFN-gamma) mediates the final damage of the stem cell compartment in Aplastic Anaemia (AA). Normal subjects homozygous for 12 (CA) repeats of polymorphism variable number of dinucleotide (CA) repeat (VNDR) in position 1349 of the IFN-gamma gene (IFNG) were shown to overproduce IFN-gammain vitro. We studied the distribution of polymorphism VNDR 1349 of IFNG in 67 Caucasian AA patients and in normal controls. Genotype (CA)12-12, (homozygosis for allele 2) and the single allele 12 were significantly more frequent (P = 0.005 and 0.004 respectively) in patients versus controls. The polymorphism was equally distributed in AA patients regardless of their response to immunosuppression. Homozygosity for 12 (CA) repeats of polymorphism VNDR 1349 of IFNG is strongly associated with the risk of AA in Caucasian subjects.
- Published
- 2004
- Full Text
- View/download PDF
48. Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulating factor regimens: a GITMO prospective randomized study.
- Author
-
Locasciulli A, Bruno B, Rambaldi A, Saracco P, Dufour C, Finelli C, Sica S, Varotto S, Arcese W, Locatelli F, Soligo D, and Bacigalupo A
- Subjects
- Adolescent, Adult, Aged, Anemia, Aplastic drug therapy, Anemia, Aplastic mortality, Animals, Blood Cell Count, Child, Child, Preschool, Disease-Free Survival, Drug Administration Schedule, Drug Therapy, Combination, Female, Granulocyte Colony-Stimulating Factor therapeutic use, Hematopoietic Stem Cell Mobilization, Horses, Humans, Immunosuppressive Agents administration & dosage, Life Tables, Male, Methylprednisolone therapeutic use, Middle Aged, Prospective Studies, Survival Analysis, Treatment Failure, Treatment Outcome, Anemia, Aplastic therapy, Antilymphocyte Serum therapeutic use, Cyclosporine therapeutic use, Granulocyte Colony-Stimulating Factor administration & dosage, Immunosuppressive Agents therapeutic use
- Abstract
Background and Objectives: In a previous study we showed that patients with severe aplastic anemia (SAA) treated with anti-lymphocyte globulin (ALG), cyclosporin (CyA) and granulocyte colony-stimulating factor (G-CSF) 5 micro g/kg/day had an encouraging outcome. However, failure to respond, delayed responses, partial responses, relapses and early deaths remain significant problems. The aim of the present study was to test whether a higher dose of G-CSF (10 micro g/kg/day) would reduce these complications., Design and Methods: This was a multicenter prospective trial in 77 SAA patients treated with horse ALG (15 mg/kg/day day1-5) and CyA (5 mg/kg/day day 1-180). Patients were randomized to receive G-CSF 5 micro g/kg/day (n=38, group A) or 10 micro g/kg/day (n=39, group B) from day +1 to day +30. All patients then received G-CSF 5 micro g/kg/day from day +31 to day +90. The primary end point of this study was response at day +120. Secondary end points were early deaths, blood counts at day +120, and survival., Results: At day +120 responses were classified as absent, partial, and complete in 12, 22, and 4 patients in group A and in 23, 7, and 9 patients in group B (p=0.001). At last follow-up these figures were respectively 9, 12, and 17 vs 19, 2, and 18 (p=0.004). Thirteen patients (5 in group A and 8 in group B) died before day 120 (p=0.3). Median peripheral blood counts on day 120 were comparable in the two groups: Hb 10.5 and 9.5 g/dL in group A and B, respectively (p=0.6), Neutrophil counts were 2.4 vs 1.9x10(9)/L in groups A and B (p=0.4) and platelet counts were, respectively, 42 vs 36x10(9)/L (p=0.3). The actuarial survival at 4 years is 72% in group A and 67% in group B (p=0.3)., Interpretation and Conclusions: Increasing the dose of G-CSF does not appear to reduce early deaths, does not improve peripheral blood counts nor survival, and may reduce the response rate in patients with SAA receiving ALG and CyA.
- Published
- 2004
49. Results and follow-up of a phase III randomized study of recombinant human-granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia.
- Author
-
Gluckman E, Rokicka-Milewska R, Hann I, Nikiforakis E, Tavakoli F, Cohen-Scali S, and Bacigalupo A
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Anemia, Aplastic blood, Child, Child, Preschool, Drug Therapy, Combination, Female, Follow-Up Studies, Granulocyte Colony-Stimulating Factor adverse effects, Humans, Immunosuppressive Agents adverse effects, Infant, Lenograstim, Leukocyte Count, Male, Middle Aged, Neutrophils pathology, Opportunistic Infections prevention & control, Recombinant Proteins adverse effects, Survival Rate, Treatment Failure, Treatment Outcome, Anemia, Aplastic drug therapy, Granulocyte Colony-Stimulating Factor therapeutic use, Immunosuppressive Agents therapeutic use, Recombinant Proteins therapeutic use
- Abstract
In patients with idiopathic severe aplastic anaemia who are treated with immunosuppressive agents to combat T lymphocyte-mediated destruction of haematopoietic progenitor cells, neutropenia is a major cause of infections and toxicity. Evidence from preliminary studies suggests that recombinant human glycosylated granulocyte colony-stimulating factor (lenograstim) increases the number and functionality of neutrophils in patients with severe aplastic anaemia. This randomized, parallel-group, multicentre study was conducted to evaluate the efficacy and safety of subcutaneous lenograstim during the first 12 weeks of standard immunosuppressive therapy in 102 patients with de novo severe aplastic anaemia. The addition of lenograstim to standard therapy resulted in an increase in the proportion of patients showing complete neutrophil response (83.0%vs 44.9%; P < 0.0001). This was seen even among patients with very severe aplastic anaemia (69.2%vs 31.6%; P = 0.012). In patients receiving lenograstim, median time to complete neutrophil response was shorter (6.3 vs 16.1 weeks; P = 0.0001) and mean duration of first neutrophil response was longer (P = 0.0248) than in the control group. At a median follow-up of 5 years, no difference was observed between the groups in term of survival, haematological response and occurrence of secondary leukaemia (one patient in each group). We conclude that lenograstim support of immunosuppressive therapy might be used for patients with severe aplastic anaemia as it significantly enhances neutrophil recovery but does not modify the overall response and survival.
- Published
- 2002
- Full Text
- View/download PDF
50. Outcome of pregnancy and disease course among women with aplastic anemia treated with immunosuppression.
- Author
-
Tichelli A, Socié G, Marsh J, Barge R, Frickhofen N, McCann S, Bacigalupo A, Hows J, Marin P, Nachbaur D, Symeonidis A, Passweg J, and Schrezenmeier H
- Subjects
- Adult, Anemia, Aplastic complications, Blood Cell Count, Female, Hemoglobinometry, Hemoglobinuria, Paroxysmal complications, Humans, Pregnancy, Pregnancy Outcome, Remission Induction, Retrospective Studies, Anemia, Aplastic drug therapy, Immunosuppressive Agents therapeutic use, Pregnancy Complications, Hematologic drug therapy
- Abstract
Background: Aplastic anemia may develop during pregnancy and sometimes improves spontaneously after delivery. The effects of pregnancy on aplastic anemia after immunosuppressive treatment and of aplastic anemia on the outcome of pregnancy have not been described., Objective: To determine the outcome of pregnancy and the disease course among women with aplastic anemia who received immunosuppressive therapy., Design: Retrospective multicenter study., Setting: Twelve centers participating in the European Group for Blood and Marrow Transplantation., Patients: 36 women who received immunosuppressive therapy to treat aplastic anemia., Measurements: Outcomes of pregnancy and aplastic anemia and blood counts before, during, and after delivery., Results: The 36 pregnancies resulted in 34 live births (one set of twins), 2 elective abortions, and 1 spontaneous abortion. Of the 36 pregnancies, 22 were uncomplicated and 14 involved medical complications. Seven pregnancies (19%) were complicated by relapse of aplastic anemia, and 5 patients without relapse (14%) needed transfusions during delivery. After delivery, 3 of the 7 patients who had relapse recovered spontaneously and 3 recovered after retreatment. One patient who did not respond to treatment died of aplastic anemia. A woman with aplastic anemia and paroxysmal nocturnal hemoglobinuria had a fatal cerebral thrombosis after delivery. Women with uneventful pregnancies had better prepregnancy remission status (8 complete and 11 partial remissions) and a higher median platelet count (146 x 10(9) cells/L) than did women with complicated pregnancies (2 complete remissions, 8 partial remissions, and 4 cases of paroxysmal nocturnal hemoglobinuria; median platelet count, 92 x 10(9) cells/L)., Conclusions: Successful pregnancy with normal outcome is possible in women with aplastic anemia previously treated with immunosuppression. Complications appear to be more likely in patients with low platelet counts and paroxysmal nocturnal hemoglobinuria-associated aplastic anemia.
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.